A Phase 1 interventional study of anle138b and Placebo in Healthy Volunteers, sponsored by MODAG GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-06.
Sponsored by MODAG GmbH · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 99th largest by enrollment of the 183 interventional ones that give a count, is one of 22 that started in 2019, is one of 26 in phase 1, and was the 135th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Northumbria University · Sites in United Kingdom
Ages 50+
Hoffmann-La Roche · Sites in United Kingdom, United States, China and 2 more countries
Ages 40–85
Heriot-Watt University · Sites in United Kingdom
Ages 18+
Queen's University, Belfast · Sites in United Kingdom
Ages 18+
University Hospital Tuebingen · Sites in United Kingdom, France, Germany and 4 more countries
Ages 35–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 48 · Phase 3 46 · Phase 4 6
First in 1999; this study’s year is marked. 22 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 68 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 80 across the 183 interventional studies, 100 across the 62 observational. Of the 152 that completed or were terminated, 45 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 246 have an industry lead sponsor. The 10 most frequent:
MODAG GmbH is the lead sponsor of 6 studies on the registry; 3 are open to participants now.
MODAG GmbH has 6 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05986643University of LeicesterBrain Training to Improve Balance in Parkinson's Disease | 2026-12 |
| NCT05635409Region SkaneA Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease | 2027-01 |
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
| NCT07882108Cambridge University Hospitals NHS Foundation TrustGinger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease | 2027-03-01 |
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability and blood levels of orally administered anle138b in healthy subjects.
This is a single-centre, study of double-blind, randomised, placebo-controlled single ascending doses (SAD) and multiple ascending doses (MAD) of anle138b in healthy subjects in study Parts 1 and 2. In study Part 3 the effect of food (FES) on the safety and PK of anle138b in healthy subjects is examined.
In the SAD cohorts, subjects will be randomly assigned to receive a single oral dose of active investigational medicinal product (IMP) or matching placebo in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.
In the MAD cohorts, subjects will be randomly assigned to receive oral doses of active IMP or matching placebo once daily (QD) for 7 days, in a sequential escalating manner with sufficient time planned between dose groups to allow interim review of the data.
In the FES, the effect of food on the safety and PK of anle138b is explored by administering a single dose of IMP after a high-fat breakfast. Subjects will be randomly assigned to one of 2 treatment sequence to receive anle138b in the fed or fasted state over 2 periods.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage: 50 mg and higher Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
Drug: anle138b
Matching placebo Dosage form: capsule Frequency: once daily Duration: One day for SAD and seven days for MAD
Drug: Placebo
capsule containing excipient and anle138b
matching placebo capsule containing excipient
Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of anle138b (Part 1)
Adverse events (AEs)
Time frame: Day 1 to day 30 post dose
Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with single ascending doses of anle138b (Part 1)
clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in vital signs in healthy volunteers with single ascending doses of anle138b (Part 1)
Blood pressure, heart rate, oral temperature
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent ECG changes in healthy volunteers with single ascending doses of anle138b (Part 1)
Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b (Part 1)
physical examination findings
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent adverse events in healthy volunteers with multiple ascending doses of anle138b (Part 2)
Adverse events (AEs)
Time frame: Day 1 to day 30 post dose
Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with multiple ascending doses of anle138b (Part 2)
clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in vital signs in healthy volunteers with multiple ascending doses of anle138b (Part 2)
Blood pressure, heart rate, oral temperature
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent ECG changes in healthy volunteers with multiple ascending doses of anle138b (Part 2)
Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in physical examination in healthy volunteers with multiple ascending doses of anle138b (Part 2)
physical examination findings
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent adverse events in healthy volunteers with a single dose of anle138b both the fasted and fed state (Part 3)
Adverse events (AEs)
Time frame: Day 1 to day 30 post dose.
Incidence of treatment-emergent changes in clinical laboratory parameters in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)
clinical laboratory tests including hematology and clinical chemistry including renal function tests, hepatic enzymes, electrolytes and creatine kinase
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in vital signs in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)
Blood pressure, heart rate, oral temperature
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent ECG changes in healthy volunteers with a single dose of anle138b both in the fasted and in the fed state (Part 3)
Electrocardiogram (ECG) parameters including QT interval corrected for heart rate using Fridericia's formula (QTcF)
Time frame: Day 1 to day 7 post dose
Incidence of treatment-emergent changes in physical examination in healthy volunteers with single ascending doses of anle138b both in the fasted and in the fed state (Part 3)
physical examination findings
Time frame: Day 1 to day 7 post dose
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Time prior to the first measurable concentration of anle138b. Time prior to the first measurable concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Time of maximum observed concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Maximum observed concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Area under the curve from 0 time to 24 h post-dose of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Area under the curve from 0 time to the last measurable concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Area under the curve from 0 time extrapolated to infinity of anle138b levels.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Slope of the apparent elimination phase of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Apparent elimination half-life of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Mean residence time from 0 time to the last measurable concentration after extravascular administration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of single (Part 1) ascending doses of anle138b in the fasted state
Mean residence time extrapolated to infinity after extravascular administration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state
Time of maximum observed concentration of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state
Maximum observed concentration of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state
Area under the curve over the dosing interval from time 0 to tau of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state
Slope of the apparent elimination phase (last dose only) of anle138b
Time frame: Day 7 to day 9
Oral pharmacokinetics (PK) of multiple (Part 2) ascending doses of anle138b in the fasted state
Apparent elimination half-life (last dose only) of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state
Accumulation Ratio based on Cmax repeated dose /Cmax single dose of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) of single (Part 1) and multiple (Part 2) ascending doses of anle138b in the fasted state
Accumulation Ratio based on area under the curve (0 tau) repeated dose/AUC(0 tau) single dose of anle138b
Time frame: Day 1 to day 9
Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states.
Maximum observed concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states.
Area under the curve from 0 time to the last measurable concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states
Area under the curve from 0 time extrapolated to infinity of anle138b levels.
Time frame: From dosing to 48 hours post dosing
Oral pharmacokinetics (PK) (Part 3) for anle138b in the fed and fasted states
Percentage of area under the curve (0-inf) extrapolated beyond the last measurable concentration of anle138b.
Time frame: From dosing to 48 hours post dosing
Plan to share: No
Ran from Dec 2019 to primary completion in Aug 2020, 7 months.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's 7 months is below that.
Counting every sponsor, half of 204 studies reached it within 19 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emrusolmin